

Synthesis some of heterocyclic Compounds of Meldrum's Acid and study of The biological Activity

Rajaa Abdul A Ghafil¹, Naji M Ali², Hassan T Ghanim³

¹Chemistry Department, Faculty of Education for girls, Iraq.

²Pharmaceutical Chemistry Department, Faculty of pharmacy, Iraq.

³Chemistry Department, Faculty of Education for girls, Iraq.

ABSTRACT

This paper involves synthesis of some heterocyclic compound derivative from Meldrum's acid, by reaction of Meldrum's acid, indol and p-hydroxy benzaldehyde and catalyst L-proline in acetonitrile to produce Meldrum's acid derivative (P), compound (P) ethanolysis to give ester derivative (P₁), the compound (P₁) reacted with hydrazine hydrate to give hydrazide derivative compound (P₂), hydrazide derivative reacted with p-hydroxy benzaldehyde in absolute ethanol to give Schiff base derivative (P₃), Schiff base derivative using to prepare some new heterocyclic compounds by multi step reactions and reactant with different solvent and materials to prepare four, five and seven ring membered. The prepared compounds were characterized by FT-IR, ¹H NMR, ¹³C NMR. All the prepared compounds were studied the antibacterial activity.

Keywords : indo, comp, character.

I. INTRODUCTION

2,2-dimethyl-4,6-dioxo-1,3-dioxane or Meldrum's acid fig.(1). The structural simplicity of Meldrum's combined with its unique properties has made this a versatile reagent in organic synthesis¹. Meldrum's acid is a highly interesting sort of compounds with biological and pharmaceutical properties². The C(5) position of MA supplies an improved and metal-free approach to construct C-C linkages in organic molecules. The unusually high acidity (pK_a of 4.83-4.936 in H₂O) of active methylene in MA at C(5) supplies direct access to the formation of a C-C framework³. Multicomponent reaction is a one-step reaction that joins two or more reactants to form an end product⁴. MCRs have been used as a multilateral synthetic method for the synthesis of complex molecules⁵. Indol is one of the most many six-membered heterocyclic nuclei, specific as a pharmacophore in a large number of natural and synthetic biologically active molecules⁶, indole nucleus are formed in interesting plants⁷. Some indol derivatives have been found with a broad spectrum of antimicrobial activity⁸.

II. MATERIALS AND METHODS

The chemical compounds have high purity as supplied by Sigma and GCC company. Melting point of the compounds recorded by electro thermal 9300, melting point engineering LTD. All measurements synthesis compounds were recorded by FTIR spectra, Fourier transform infrared Shimadzu (8400), ¹H NMR and ¹³C NMR – spectra (in ppm) in DMSO solvent by AVANCE AQS-300MHz, Iran. Thin layer chromatography used silica gel in (Benzene:methanol) solvent.

Experimental

Synthesis of the compound (P)

By reaction between indol (1.17 gm, 0.01 mol) in CH₃CN (10 ml), Meldrum's acid⁹ (1.14 gm, 0.01 mol), p-hydroxy benzaldehyde (1.22 gm, 0.01 mol) and L-proline (0.06 gm, 0.0005 mol). The mixture was stirred at 25-30°C⁰ for 47 hours. The product was dissolved in absolute ethanol and recrystallized.

Synthesis of ester derivative of compound (P₁)


The compound derivative was prepared by mixture of the Meldrum's acid derivative (1 equiv) and copper (0.2 equiv) was dissolved using a mixture of (10:1) pyridine/ethanol (0.1 M) solution¹⁰. The mixture was refluxed to 100°C⁰ for 3 hours. Removal of the Cu powder the product was recrystallized from ethyl acetate/n-hexane.

Synthesis of hydrazide¹¹ derivative of compound (P₂)

The compound derivative (P₂) (1 gm, 0.01 mol) reacted with hydrazine hydrate (0.5 gm, 0.01 mol) in absolute ethanol. The mixture was heated and stirred under reflux to 78°C⁰ for 21 hours. The product recrystallized from absolute ethanol.

Synthesis of Schiff base derivative¹² of compound (P₃)


Schiff base compound was prepared by reaction between p-hydroxy benzaldehyde (0.3 gm, 0.002 mol) and hydrazide compound (S₂) (0.6 gm, 0.002) as catalyst in the glacial acetic acid 2-3 drops, The mixture was heated under reflux to 78°C⁰ for 15 hours to produce compound (P₃) which recrystallized from ethanol.



Scheme (1): synthesis of compounds (P to P₃)

Synthesis of β -lactam derivative¹³ (P₄)


The compound (P₄) was prepared by reaction between the compound P₃ (0.001 mol, 0.5 gm) and tri ethyl amine (0.001 mol) and chloro acetyl chloride (0.001) in 1,4-dioxane, The mixture was stirred at (15-20)C⁰ for 20 hours, to produce the compound P₄, The products, which crystallized from absolute ethanol.



Scheme (2): synthesis of the compound (P₄)

Synthesis of the oxazepine derivatives¹⁴ (P₅, P₆).


The compounds (P₅-P₇) were prepared by reaction between Schiff base derivative (P₃) (0.01 mol) with (0.01 mol) for (phthalic and malice), anhydride respectively in the dry benzene the mixture were refluxed at 60 C⁰ for 30 hours, Scheme (3).



Scheme (3): synthesis of the compounds (P₅,P₇)

Synthesis of oxazepane derivative (P₇)¹⁵


A compound of Schiff base derivatives(P₃) (0.01 mol) and succinic anhydride (2mol) were dissolved in dry benzene (20ml) under reflux in oil bath 60⁰C. A precipitate was formed. That are filtered under cool condition to afford oxazepane and recrystallization of the product take place by ethanol.



Scheme (3): synthesis of the compound(P₇)

Synthesis of the compounds (P₈,P₉)¹⁶

The compounds (P₈-P₉) were prepared by the reaction between Schiff base derivative compound P₃ (0.01mol) with amino acid (glycine and alanine) (0.01 mol) respectively in tetra hydro furan and the mixture was refluxed at 60⁰C for 25 hours , The products which recrystallized from absolute ethanol, Scheme (4).



Scheme (4): synthesis of compounds (P₈,P₉)

2-4 Study of the biological activity of the compound by paper technique disks¹⁷.

Antibacterial activity was measured by using filtering paper type (whiteman NO.1) to prepared (120) pills after purification, after that, the pills put in the test tube average (5) pills for every tube and added (1 ml) from syntheses compounds solution. were used weight of (5mg, 10 mg, 20mg) from the synthesis compounds.

III. RESULTS AND DISCUSSION

P: 5-[(4-hydroxy-phenyl)-(1H-indol-3-yl)methyl]-2,2-dimethyl-[1,3]dioxane-4,6-dione, M.P(92-94) °C⁰, yield % 77, FT-IR(KBr) cm⁻¹ ν3414 (OH), ν 3200 (NH_{indol}), ν3057 (CH_{aromatic}), ν2935-2806 (CH_{aliphatic}), ν1749, 1687 (C=O)_{ester}, ν 1298 (C-O).

P₁: Ethyl-3-(1H-indol-3-yl)-3-(4-hydroxyphenyl)propanoate, M.P(93-95) °C⁰, yield % 77, FT-IR(KBr) cm⁻¹, ν3433 (OH), ν 3226 (NH_{indol}), ν3064 (CH_{aromatic}), ν2926-2856 (CH_{aliphatic}), ν 1732 (C=O, ester), ν1564-1602 (C=C)_{aromatic}, ν1280 (C-O), ¹H-NMR(DMSO), δ11.1 (s, 1H), OH_{phenol} 10.3 (s, 1H), NH_{indol}, δ 6.8-7.7 (m, aromatic ring), δ3.576-3.542 (m, CH_{2O})_{ester}, 1.9 (d, 2H), δ 1.1 (t, 3H)_{ester}. ¹³CNMR(DMSO), δ174 C for (C=O)_{ester}, δ156 C for (OH)_{phenol}, δ116-142 C for aromatic ring, δ15 C for (CH₃)_{ester}¹⁸, δ 60 C for (CH₂)_{ester}.

P₂: 3-(4-hydroxyphenyl)-3-(1H-indol-3-yl)propionic acid hydrazide, M.P(188-190) °C⁰, yield % 82, FT-IR(KBr) cm⁻¹, 3454, 3425 (NH₂), ν3332 (NH_{amide}), ν1641 (C=ONH), ν1618-1529 (C=C)_{aromatic}, ¹H-NMR(DMSO), δ 11.7 (s, OH), δ 10.2 (s, NH_{indol}), δ 9.2 (s, 1H, C=ONH)¹⁹, 6.3 (s, 2H, NH₂)_{amide}, δ6.9-7.7 (m, aromatic ring) ¹³CNMR(DMSO), δ170 C for (C=O)_{amide}, δ 125-133 C for aromatic ring.

P₃: 3-(4-Hydroxyphenyl)-3-(1H-indol-3-yl)-propionic acid (4-hydroxy-benzylidene)-hydrazide, M.P(223-225) °C⁰, yield % 76, FT-IR(KBr) cm⁻¹, ν3448 (OH), ν 3423 (NH_{amide}), ν3077 (CH_{aromatic}), ν2995-2850 (CH_{aliphatic}), ν1640 (C=ONH_{amide}), ν1624 (C=N_{schiff base})²⁰, ν1589 (C=C)_{aromatic}, ¹H-NMR(DMSO), δ11.7 (s, OH), δ8.6 (s, 1H, N=CH)_{schiff base}, ¹³CNMR(DMSO), δ171 C for (C=O)_{amide}, δ158 C for (C=N)_{imine}, δ155 C for (OH), δ 126-142 C for aromatic ring.

P₄: N-[3-chloro-2-(4-hydroxy-phenyl)-4-oxo-azetidino-1-yl]-3-(4-hydroxyphenyl)-3-(1H-indol-3-yl)propionamide, M.P(250-253) °C⁰, Yield 76% FT-IR(KBr) cm⁻¹ ν3448-3421, (OH), ν 3082 (NH_{indol}), ν 3062 (CH_{aromatic}), ν1674 (C=O)_{Lactam}, ν1620-1573 (C=C)_{aromatic}, ν 800-600 (C-Cl), ¹H-NMR(DMSO), δ11.7 (s, 1H, OH), δ8.8-8.9 (d, 1H, N-CH)_{lactam ring}, δ 6.9-7.9 (m, aromatic ring), δ3.4 (s, 1H, CHCl), ¹³CNMR(DMSO), δ185 C for (C=O)_{Lactam ring}, δ 171 C for (C=O)_{amide}, δ 159 C for (N-CH)_{lactam ring}, δ 154 C for (C-OH)_{phenol ring}, δ116-133 C for Aromatic ring, δ43 C for (C-Cl).


P₅: 3-(4-hydroxy-phenyl)-N-[7-(4-hydroxy-phenyl)-5,9-dioxo-5,9-dihydro-6-oxa-benzocyclohepten-8-yl]-3-(1H-indol-3-yl)-3-phenylpropionamide, M.P(318-320) °C⁰, Yield % 80, FT-IR(KBr) cm⁻¹, ν 3410 (OH), ν1724 (O-C=O)_{lacton}, ν1662 (N-C=O)_{lactam}, ν1643 (N-C=O), ν1600 (C=C)_{aromatic}, ¹H-NMR(DMSO), δ11.4 (s, 1H, OH), δ10.1 (sm 1H, NH)_{indol}, δ 9.3 (s, 1H, NH)_{amide}, δ8.9 (s, 1H, N-CH)_{oxazepine ring}, δ7.4-7.8 (m, aromatic ring), ¹³CNMR(DMSO), δ179, 174 C for C=O lactone and lactam respectively, δ158 C for (N-CH)_{ring oxazepine}, δ125-133 C for aromatic ring.

P₆: N-[2-(2-hydroxy-phenyl)-4,7-dioxo-4,7-dihydro-[1,3]oxazepan-3-yl]-3-(1H-indol-3-yl)-3-phenylpropionamide, M.P(304-306) °C⁰, Yield % 83, FT-IR(KBr) cm⁻¹, ν3404 (OH), ν1724 (O-C=O)_{lacton}, ν1710 (N-C=O)_{lactam}, ν1622 (C=C)_{alkene}, ν (C=C)_{aromatic}, ¹H-NMR(DMSO), δ11.7 (s, 1H, OH), δ 10.1 (s, 1H, NH)_{indol}, δ6.9-6.92 (d, CH=CH)_{alkene}²¹, δ 7-8.1 (m, aromatic ring). ¹³CNMR(DMSO), δ 179, 173 C for (C=O) lactone and lactam respectively, δ160 C for (C=O)_{amide}, δ 33, 26 C for C CH₂C=O, CH₂O, δ125-133 (aromatic ring).






P₇: 3-(4-hydroxyphenyl)-N-[2-(4-hydroxy-phenyl)-4,7-dioxo-4,7-dihydro-[1,3]oxazepan-3-yl]-3-(1H-indol-3-yl)-3-phenylpropionamide, M.P (377-379) °C⁰, Yield % 83 FT-IR(KBr) cm⁻¹, ν3429 (OH), ν 3226 (NH_{amide}), ν3059 (CH_{aromatic}), ν1695 (O-C=O)_{lacton}, ν1670 (N-C=O)_{lactam}, ¹H-NMR(DMSO), δ11.5 (s, 1H, OH), δ 10.00 (s, 1H, NH)_{indol}, δ8.5, δ 1.8, 1.2 (s, 2H) for lactone and lactam respectively, (1H, N-CH), ¹³CNMR(DMSO), δ 179, 173 C for (C=O) lactone and lactam respectively, δ160 C for (C=O)_{amide}, δ 33, 26 C for C CH₂C=O, CH₂O, δ125-133 (aromatic ring).

P₈: 3-(4-Hydroxyphenyl)-N-[2-(4-hydroxy-phenyl)-5-oxoimidazolidin-1-yl]-3-(1H-indol-3-yl)-propionamide, M.P(355-357) °C⁰, Yield % 78, FT-IR(KBr) cm⁻¹, ν3408 (OH), 3330 (NH)_{Imidazolidine}, ν1726 (C=O)_{Imidazolidine}, ν1662 (C=O)_{amide} ¹H-NMR(DMSO), δ11.7 (s, 1H, OH), δ 9.9 (s, 1H, NH)_{Imidazolidine}, δ6.4 (s, 2H, CH₂)_{Imidazolidine}, 7.2-8 (m, aromatic ring), ¹³CNMR(DMSO), δ 177 C for (C=O)_{Imidazolidine ring}, δ 160 (N-CH), δ 107-137 (aromatic ring), δ148 C for (C-OH), δ54 C for (CH₂).

P₉ : 3-(4-Hydroxy-phenyl)-N-[2-(4-hydroxy-phenyl)-4-methyl-5-oxo-imidazolidin-1-yl]-3-(1H-indol-3-yl)-propionamide, M.P(370-372) C, Yield % 85, FT-IR(KBr)cm⁻¹, ν 3415, (OH), ν 3202 (NH_{Imidazolidine} ν 3024, ν 1639(C=O)_{amide}, ¹H-NMR(DMSO), δ 8.9 (CH_{aromatic}), ν 2916-2851 (CH_{aliphatic}), ν 1676(C=O)_{Imidazolidine} (1H,NH)_{Imidazolidine} δ 8.1(s,1H,N-CH), ¹³CNMR(DMSO), δ 176 C for (C=O)_{Imidazolidine ring}, 163C for (C=O) (N-CH).



Scheme (1):FT-IR spectrum of the compound (P).

Scheme (2):FT-IR spectrum of the compound (P₁).Scheme (3):FT-IR spectrum of the compound (P₂).Scheme (4):FT-IR spectrum of the compound (P₃)Scheme (5):¹H-NMR spectrum of the compound (P₁).Scheme (6):¹H-NMR spectrum of the compound (P₂).Scheme (7):¹H-NMR spectrum of the compound (P₃).





Scheme (8): ^1H NMR spectrum of the compound (P_4).Scheme (9): ^{13}C NMR spectrum of the compound (P_1).Scheme (10): ^{13}C NMR spectrum of the compound (P_2).Scheme (11): ^{13}C NMR spectrum of the compound (P_3).

Table 1: physical properties of synthesis compounds

NO	M.F	M.P	R _F	color	yield %	solvent
P	$\text{C}_{21}\text{H}_{19}\text{NO}_5$	92-94	0.8	yellow	77	Aceto nitrile
P₁	$\text{C}_{19}\text{H}_{19}\text{NO}_3$	93-96	0.6	yellow	77	Ethanol\pyridine
P₂	$\text{C}_{17}\text{H}_{17}\text{N}_3\text{O}_3$	188-190	0.75	Red	82	ethanol
P₃	$\text{C}_{24}\text{H}_{13}\text{N}_3\text{O}_3$	223-225	0.93	yellow	76	ethanol
P₄	$\text{C}_{25}\text{H}_{21}\text{N}_3\text{O}_4$	250-253	0.91	yellow	76	1,4-dioxane
P₅	$\text{C}_{32}\text{H}_{22}\text{N}_3\text{O}_6$	318-320	0.82	Yellow	80	Dry benzene
P₆	$\text{C}_{28}\text{H}_{23}\text{N}_3\text{O}_6$	304-306	0.75	yellow	83	Dry benzene
P₇	$\text{C}_{28}\text{H}_{25}\text{N}_3\text{O}_6$	377-379	0.79	yellow	83	Dry benzene
P₈	$\text{C}_{24}\text{H}_{24}\text{N}_4\text{O}_4$	353-355	0.81	Yellow	78	Tetra hydro furan
P₉	$\text{C}_{24}\text{H}_{26}\text{N}_4\text{O}_4$	370-377	0.73	yellow	85	Tetra hydro furan

Table 2: Antibacterial Activity of synthetic compounds

Type of bacteria Comp.NO.	inhibition zone(mm) 5mg 10mg 20mg (mg\mol)			
	<i>klebsiella pneumonia</i>	<i>Staphylococcus</i>	<i>Enterococcus faecalis</i>	<i>pseudomonas aeruginosa</i>
P	-,5,8	-, -, 6	-, -,6	-, -,6
P₁	-, -,5	-, -, 5	-, -,8	-, -,8

P ₂	-	-, -, 4	-, -, 10	-, -, 8
P ₃	-, -, 8	-, 5, 8	-, -, -	-, -, 6
P ₄	10, 12, 25	10, 15, 40	-, 10, 15	-, -, 10
P ₅	-	-, -, 10	-, 8, 10	-, -, 7
P ₆	-	-	-	-, 10, 15
P ₇	-, -, 5	-, 5, 10	-, -, 10	-, 6, 8
P ₈	-, -, 8	-, -, 22	-, 6, 12	-, -, 8
P ₉	-, -, 10	-, -, 10	-, -, 8	-, -, 8

REFERENCES

1. Caroline R.M.Doca, Fabriciof Naciuk and others ., *J.Braz .Chem.Soc.*, 28,2,(2017).
2. E Imaira K , Nader N. Pesyan ,T. and Ertan S ., *.j.chin. Chem. Soc.*,62.(2015).
- 3.Haroon M ,Aamer S. and others ., *Crystals*,7(211) :1-4,(2017).
- 4.Riat S. ,Agarwal D. and M.C.Agarwal .*I nternational Journal of Scientific Research and Growth*,1(6):174-193,(2017).
5. Caroline R.,Fabricio F. and others ., *J.Braz.Chem.Soc.*, 28(2):285-298 ,(2017).
6. Grazilla T. ,Gloria Z. and others ., *Molecules* , 22,1747,(2017).
7. Adriana V. ,Pedro De-La-Torre and Margarita I., *Journal of Chemistry* ,ID 841893 :1-8 ,(2017).
8. Tomio S. ,Mai I. and Keimel O., *International of Chemical EngineerinG and Application* , 8(3) ,(2017).
9. .Meldrum,*J.Chem.Soc.*, 93,598-601,(1908).
10. Oikawa Y.;Hirasawa H .,Yonemistus O.Tetrahedron Lett.,19,1759-1762.(1978).
11. Haydr Ghainum and Hasan Thamr .*J.Chem.Pharm.Res.*,9(1),93-99,(2017).
12. Muhammad Nawaz T ,Naghmana Kausar and others.,*Am-Euras.J.Agric &Environ .Sci.*, 15(12) : 2479-2483,(2015).
13. Ranza A.Elrayess,Nagat Ghareb and others., *Life Science Journal*,10(3),1784-1793,(2013).
- 14.Safa T. ,Hasan T., *Int. Journal of Chem.Tech Research* ,9(9) :360-367,(2017).
15. Muna S. Al-Rawy, Jumbud H and Dhuha F.,*Iraqi National Journal of Chemistry*, 55,264-274,(2014).
16. Vivek G and A. Pandurangan., *American Journal of Advanced Drug* ,1(4):413-421,(2013).
17. K.Bauer ; *J.Amer.Clin.Path*,45,493,(1966).
18. Luay Abu-Qatouseh ,Mohammad Abu-Sini and others ., *Molecules* ,22,71,(2017).
- 19.Bhushan Nazirkar ,Udaysingh Patil and others ., *Der .Pharma.Chemica.*, 9(3) :45-53,(2017).
20. Ruwaida Asyikin ,Meng Guan and Hashimatul Fatma , *Malaysian Journal of Analytical Sciences* .,21(5) :1168-1175 ,(2017).
21. Safa .Thaier and Hasan Thamr , *Inter.Jour.Of Chem Tech Reser.*,9(9):360-367,(2016).